BIO – Bio-Rad Laboratories, Inc.
Float Short %
4.53
Margin Of Safety %
41
Put/Call OI Ratio
0.21
EPS Next Q Diff
0.02
EPS Last/This Y
-17.6
EPS This/Next Y
1.1
Price
271.27
Target Price
335
Analyst Recom
2
Performance Q
-11.85
Upside
126.4%
Beta
1.19
Ticker: BIO
of 1
| Date | Symbol | Latest | P/C OI | P/C Vol | Total OI |
|---|---|---|---|---|---|
| 2026-01-23 | BIO | 296.35 | 0.07 | 0.00 | 585 |
| 2026-01-26 | BIO | 299.27 | 0.06 | 0.09 | 642 |
| 2026-01-27 | BIO | 297.64 | 0.06 | 0.00 | 666 |
| 2026-01-28 | BIO | 299.73 | 0.07 | 3.00 | 630 |
| 2026-01-29 | BIO | 294.65 | 0.09 | 1.00 | 642 |
| 2026-01-30 | BIO | 293.09 | 0.09 | 999.99 | 644 |
| 2026-02-02 | BIO | 297.33 | 0.09 | 0.00 | 645 |
| 2026-02-04 | BIO | 305.94 | 0.09 | 0.00 | 685 |
| 2026-02-05 | BIO | 299.39 | 0.09 | 0.00 | 687 |
| 2026-02-06 | BIO | 302.76 | 0.09 | 999.99 | 687 |
| 2026-02-09 | BIO | 294.83 | 0.09 | 11.77 | 687 |
| 2026-02-10 | BIO | 300.09 | 0.32 | 50.00 | 849 |
| 2026-02-11 | BIO | 293.86 | 0.40 | 0.00 | 900 |
| 2026-02-12 | BIO | 292.06 | 0.39 | 0.19 | 905 |
| 2026-02-13 | BIO | 256.47 | 0.32 | 1.80 | 2916 |
| 2026-02-18 | BIO | 270.04 | 0.21 | 0.00 | 2888 |
| 2026-02-19 | BIO | 271.5 | 0.21 | 0.00 | 2889 |
| Date | Symbol | Latest | P/C OI | P/C Vol | Total OI |
Current Page1 of 1
of 1
| Date | Ticker | Price | Current Quarter Growth Estimate | EBIT Estimation | Average EPS Estimate Current Year |
|---|---|---|---|---|---|
| 2026-01-23 | BIO | 296.35 | -6.6 | 1111.2 | 9.95 |
| 2026-01-26 | BIO | 299.28 | -6.6 | 1122.0 | 9.95 |
| 2026-01-27 | BIO | 297.57 | -6.6 | 1117.7 | 9.95 |
| 2026-01-28 | BIO | 299.34 | -6.6 | 1121.0 | 9.95 |
| 2026-01-29 | BIO | 294.19 | -6.6 | 1113.5 | 9.95 |
| 2026-01-30 | BIO | 293.72 | -6.6 | 1117.3 | 9.95 |
| 2026-02-02 | BIO | 297.60 | -6.6 | 1122.7 | 9.95 |
| 2026-02-03 | BIO | 298.81 | -6.6 | 1124.3 | 9.95 |
| 2026-02-04 | BIO | 305.83 | -6.6 | 1128.5 | 9.95 |
| 2026-02-05 | BIO | 299.72 | -6.6 | 1115.7 | 9.95 |
| 2026-02-06 | BIO | 301.25 | -6.6 | 1124.3 | 9.95 |
| 2026-02-09 | BIO | 294.63 | -6.6 | 1114.0 | 9.95 |
| 2026-02-10 | BIO | 300.22 | -6.6 | 1126.1 | 9.95 |
| 2026-02-12 | BIO | 291.97 | -6.6 | 1118.0 | 9.95 |
| 2026-02-18 | BIO | 270.21 | -22.0 | -660.3 | 10.31 |
| 2026-02-19 | BIO | 271.50 | -22.0 | - | 10.31 |
| 2026-02-20 | BIO | 271.27 | -22.0 | - | 10.27 |
| Date | Ticker | Price | Current Quarter Growth Estimate | EBIT Estimation | Average EPS Estimate Current Year |
Current Page1 of 1
of 1
| Date | Ticker | Insider Transactions | Institutional Transactions | Float Short |
|---|---|---|---|---|
| 2026-01-23 | BIO | -0.01 | 5.42 | 4.78 |
| 2026-01-26 | BIO | -0.01 | 8.93 | 4.78 |
| 2026-01-27 | BIO | -0.01 | 8.93 | 4.78 |
| 2026-01-28 | BIO | -0.01 | 8.93 | 4.38 |
| 2026-01-29 | BIO | -0.01 | 8.93 | 4.38 |
| 2026-01-30 | BIO | -0.01 | 8.93 | 4.38 |
| 2026-02-02 | BIO | -0.01 | 7.82 | 4.38 |
| 2026-02-03 | BIO | -0.01 | 7.82 | 4.38 |
| 2026-02-04 | BIO | -0.01 | 7.82 | 4.38 |
| 2026-02-05 | BIO | -0.01 | 7.82 | 4.38 |
| 2026-02-06 | BIO | -0.01 | 7.82 | 4.38 |
| 2026-02-09 | BIO | -0.01 | 4.45 | 4.38 |
| 2026-02-10 | BIO | -0.01 | 4.45 | 4.38 |
| 2026-02-11 | BIO | -0.01 | 4.45 | 4.53 |
| 2026-02-12 | BIO | -0.01 | 4.45 | 4.53 |
| 2026-02-13 | BIO | -0.01 | 4.45 | 4.53 |
| 2026-02-17 | BIO | -0.01 | 3.07 | 4.53 |
| 2026-02-18 | BIO | -0.01 | 3.07 | 4.53 |
| 2026-02-19 | BIO | -0.01 | 3.07 | 4.53 |
| 2026-02-20 | BIO | -0.01 | 3.07 | 4.53 |
| Date | Ticker | Insider Transactions | Institutional Transactions | Float Short |
Current Page1 of 1
Last Quarter Act. EPS
2.51
Avg. EPS Est. Current Quarter
1.98
Avg. EPS Est. Next Quarter
2.53
Insider Transactions
-0.01
Institutional Transactions
3.07
Beta
1.19
Average Sales Estimate Current Quarter
585
Average Sales Estimate Next Quarter
658
Fair Value
383.28
Quality Score
93
Growth Score
41
Sentiment Score
41
Actual DrawDown %
67.4
Max Drawdown 5-Year %
-73.8
Target Price
335
P/E
9.72
Forward P/E
23.48
PEG
2.82
P/S
2.83
P/B
0.98
P/Free Cash Flow
19.54
EPS
27.92
Average EPS Est. Cur. Y
10.27
EPS Next Y. (Est.)
11.37
Target Price Estimates Raised
Target Price Estimates Lowered
Profit Margin
29.42
Relative Volume
1.14
Return on Equity vs Sector %
-18.8
Return on Equity vs Industry %
-7.5
EPS 1 7Days Diff
0.2
EPS 1 30Days Diff
0.12
EBIT Estimation
Bio-Rad Laboratories, Inc.Sector: Healthcare
Industry: Medical Devices
Employees: 7450
Bio-Rad Laboratories, Inc. develops, manufactures, and distributes life science research and clinical diagnostic products in the United States, Europe, Asia, Canada, Latin America, and internationally. It operates through two segments, Life Science and Clinical Diagnostics. The Life Science segment develops, manufactures, and markets instruments, systems, reagents, and consumables to separate, purify, characterize, and quantify biological materials, including cells, proteins, and nucleic acids used in research and biopharmaceutical laboratory environments, as well as for biopharmaceutical manufacturing, quality control process, food safety, and science education applications. This segment serves universities and medical schools, industrial research organizations, government agencies, pharmaceutical manufacturers, biotechnology companies, food producers, and testing laboratories. Its Clinical Diagnostics segment designs, manufactures, markets, and supports diagnostic test systems, informatics systems, test kits, and specialized quality controls for clinical, hospital, diagnostic reference, and transfusion and physician office laboratories, as well as software. The company offers its products through its direct commercial organization, as well as through distributors, agents, brokers, and resellers. Bio-Rad Laboratories, Inc. was founded in 1952 and is headquartered in Hercules, California.
stock quote shares BIO – Bio-Rad Laboratories, Inc. Stock Price stock today
news today BIO – Bio-Rad Laboratories, Inc. stock forecast ,stock prediction 2023 2024 2025
marketwatch BIO – Bio-Rad Laboratories, Inc. yahoo finance google finance
stock history BIO – Bio-Rad Laboratories, Inc. invest stock market
stock prices BIO premarket after hours
ticker BIO fair value insiders trading